Madrigal Pharmaceuticals, Inc. (MDGL) Segment Reporting, Other Segment Item, Amount — Quarterly & Annual

Screener

Segment Reporting, Other Segment Item, Amount at other companies

PRA GroupPRAA

$35.48M-6.5%

ConocoPhillipsCOP

$7.45B+42.3%

Matthews InternationalMATW

-$15.63M-883%

Collegium Pharmaceutical, Inc.COLL

$25.48M+4,316%

Radiant LogisticsRLGT

-$271K-113%

Microbot MedicalMBOT

$557K+7.3%

Segments

By segment

Reportable Segment$1.63M+133%

Other financials

Income statement

Revenue$364.3M+71.2%

Gross profit$43.5M—

Operating income-$56.3M-19.3%

Net income-$57.9M-37.0%

EPS (diluted)-$1.99-4.7%

Balance sheet

Cash & equivalents$292.9M+53.2%

Total debt$377.9M+179%

Total equity$523.7M-24.7%

Total assets$1.2B+22.6%

Cash flow

Operating cash flow-$167.4M-88.4%

CapEx$4.3M—

Free cash flow-$171.3M-92.7%

Valuation

Market cap$11.88B+57.6%

Enterprise value$11.96B+59.9%

P/S9.3×-5.4×

Profitability

Gross margin96.5%—

Operating margin-25.1%-9.2pp

Net margin-25.3%-8.8pp

FCF margin-59.8%-29.6pp

Returns & leverage

Return on equity-53.3%+47.0pp

Debt / equity0.7×+0.5×

Current ratio3.2×-1.9×